Incyte Corp. has entered into a definitive agreement to acquire Escient Pharmaceuticals, a clinical-stage drug discovery and development company advancing small molecules for systemic immune and neuro-immune disorders, for $750 million plus Escient’s net cash remaining at the close of the transaction.   The acquisition includes EP262, a first-in-class, potent, highly selective, once-daily small molecule antagonist of Mas-related G protein-coupled receptor X2 (MRGPRX2) and EP547, a first-in-cla...